感染症診断市場 – 2030年までの世界予測

この調査レポートでは、感染症診断市場を、製品とサービス（試薬、キット、消耗品、機器、ソフトウェアとサービス）、検査の種類（臨床検査、PoC検査）、病気の種類（肝炎、HIV、院内感染、蚊媒介性疾患、HPV、クラミジア・トラコマティス、淋菌、結核、インフルエンザ、梅毒、その他の感染症）、サンプルの種類（血液、血清、血漿、尿、その他のサンプルの種類）、技術（免疫診断、ポリメラーゼ連鎖反応、臨床微生物学、等温核酸増幅技術、DNAシーケンシングと次世代シーケンシング、DNAマイクロアレイ、その他の技術）、臨床用途（診断とスクリーニング）、エンドユーザー（診断ラボ、病院と診療所、学術研究機関、その他のエンドユーザー）別に分類しています。感染症診断市場は、北米、ヨーロッパ、アジア太平洋、ラテンアメリカ、中東・アフリカの4つの地域にまたがって成長しています。本レポートは、感染症診断市場の成長に影響を与える主要な要因（推進要因、制約要因、機会、課題など）に関する詳細な情報を網羅しています。主要企業を徹底的に分析することで、それぞれの事業概要、ソリューション、主要戦略、買収・契約に関する洞察を提供しています。新製品・新サービスの発売、そして最近の感染症診断市場の動向についても解説しています。本レポートは、感染症診断市場エコシステムにおける新興企業の競合分析も網羅しています。

本レポートは、感染症診断市場全体および各サブセグメントの収益数値の近似値に関する情報を提供し、市場リーダー企業および新規参入企業にとって役立ちます。また、本レポートは、ステークホルダーが競争環境を理解し、事業のポジショニングを改善し、適切な市場開拓戦略を策定するための洞察を深めるのに役立ちます。さらに、本レポートは、ステークホルダーが市場の動向を把握し、主要な市場牽引要因、制約要因、機会、課題に関する情報を提供するのにも役立ちます。

感染症診断市場は、2025年の265億8,000万米ドルから2030年には422億米ドルに達し、予測期間中に9.7%の年平均成長率（CAGR）で成長すると予測されています。市場の成長を牽引する要因としては、分散型診断への関心の高まりと、CLIA免除のポイントオブケア（PoC）検査の需要増加が挙げられます。これらの傾向は、PoC技術の普及に大きく貢献しています。効率的な医療サービスの提供に対するニーズが、分散型PoC検査への移行を促しています。診断検査をポイントオブケアの現場に移すことで、医療提供者は患者のそばで直接診断を行うことができ、検体採取から結果を得るまでの時間を最小限に抑えることができます。

The infectious disease diagnostics market is projected to reach USD 42.20 billion by 2030 from USD 26.58 billion in 2025, at a CAGR of 9.7% during the forecast period. The factors driving the market growth include the increasing emphasis on decentralized diagnostics and the rising demand for CLIA-waived point-of-care (PoC) tests. These trends have significantly contributed to the widespread adoption of PoC technologies. The need for efficient healthcare delivery primarily fuels the shift towards decentralized PoC testing. By relocating diagnostic testing to point-of-care settings, healthcare providers can perform diagnostics directly at the patient’s side, minimizing the time between sample collection and results.

By type of testing, the PoC testing segment is expected to grow at the highest CAGR during the forecast period.

By type of testing, the infectious disease diagnostics market is segmented into laboratory and PoC testing. The PoC testing segment is expected to grow at the highest CAGR during the forecast period. The high growth rate of this segment is attributed to the increasing investments from key companies, with a strong emphasis on innovation through product launches & strategic acquisitions. PoC testing offers several advantages over traditional laboratory testing, particularly in clinical & hospital settings. A key benefit of PoC testing is its rapid turnaround time, enabling enhanced diagnostic decisions. Moreover, PoC testing typically requires smaller sample volumes, making it less invasive and efficient.

By technology, the DNA sequencing & next-generation sequencing segment is expected to grow at the highest CAGR during the forecast period.

The infectious disease diagnostics market is segmented into immunodiagnostics, clinical microbiology, polymerase chain reaction, isothermal nucleic acid amplification technology, DNA sequencing & next-generation sequencing, DNA microarray, and other technologies. The DNA sequencing & next-generation sequencing segment is projected to register the highest CAGR during the forecast period. DNA sequencing is a user-friendly platform that is easily implemented in clinical settings to deliver rapid results. Its ability to analyze genetic material has expanded its potential across applications, including personalized medicine, cancer research, and drug discovery. Moreover, advancements in sequencing technologies, broadening applications across multiple domains, and the rising demand for personalized medicine are key factors expected to support the growth of this market segment in the coming years.

By region, the Asia Pacific region is projected to grow at the highest CAGR during the forecast period.

The market is segmented by region into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is expected to experience the highest growth rate during the forecast period. Emerging economies in this region are seeing consistent GDP growth and a notable rise in disposable income, which has been attributed to rising healthcare spending and the uptake of advanced diagnostics. Additional growth drivers include the rising incidence & prevalence of infectious diseases, modernization of healthcare infrastructure, and the increasing adoption of advanced diagnostic technologies, particularly in rural areas.

The break-up of the profile of primary participants in the infectious disease diagnostics market:

• By Company Type: Tier 1 – 40%, Tier 2 – 30%, and Tier 3 – 30%
• By Designation: C-level – 27%, D-level – 18%, and Others – 55%
• By Region: North America – 51%, Europe – 21%, the Asia Pacific – 18%, Latin America – 6%, and the Middle East & Africa- 4%

The key players in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Abbott (US), Danaher Corporation (US), bioMérieux (France), Thermo Fisher Scientific Inc. (US), Siemens Healthineers AG (Germany), Becton, Dickinson and Company (US), Revvity, Inc. (US), Hologic, Inc. (US), QIAGEN N.V. (Netherlands), Seegene Inc. (South Korea), QuidelOrtho Corporation (US), Grifols, S.A. (Spain), DiaSorin S.p.A (Italy), Bio-Rad Laboratories, Inc. (US), Sysmex Corporation (Japan), OraSure Technologies, Inc. (US), Co-Diagnostics, Inc. (US), SD Biosensor, INC. (South Korea), BIOSYNEX SA (France), Trinity Biotech (Ireland), Bruker (US), Genetic Signatures Ltd. (Australia), Epitope Diagnostics, Inc. (US), Trivitron Healthcare (India), Meril Life Sciences Pvt. Ltd. (India), InBios International, Inc. (US), Unijogen Oy (Finland), Vela Diagnostics (Singapore), and Molbio Diagnostics Limited (India).

Research Coverage:

This research report categorizes the infectious disease diagnostics market by product & service (reagents, kits, and consumables, instruments, and software & services), by type of testing (laboratory testing, PoC testing), by disease type (hepatitis, HIV, hospital-acquired infections, mosquito-borne diseases, HPV, Chlamydia trachomatis, Neisseria gonorrhea, tuberculosis, influenza, syphilis, and other infectious diseases), by sample type (blood, serum, and plasma, urine, and other sample types),  by technology (immunodiagnostics, polymerase chain reaction, clinical microbiology, isothermal nucleic acid amplification technology, DNA sequencing & next-generation sequencing, DNA microarray, and other technologies), by clinical application (diagnostics and screening), by end user (diagnostic laboratories, hospitals & clinics, academic research institutes, and other end users), and region (North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa). The report’s scope covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the infectious disease diagnostics market. A thorough analysis of the key industry players has provided insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product & service launches and recent infectious disease diagnostics market developments. This report covers the competitive analysis of upcoming startups in the infectious disease diagnostics market ecosystem.

Reasons to Buy this Report:

The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall infectious disease diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (Rising prevalence of infectious diseases, rising focus on R&D and funding investments for infectious disease diagnostic products, adoption of innovative & advanced technologies for infectious disease diagnosis, gradual shift from centralized laboratories to decentralized POC testing centers), opportunities (high growth potential of emerging economies), restraints (unfavorable reimbursements), and challenges (stringent regulatory guidelines for ivd products, operational barriers and shortage of skilled laboratory technicians) influencing the growth of the infectious disease diagnostics market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the infectious disease diagnostics market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the infectious disease diagnostics market across varied regions.
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the infectious disease diagnostics market

Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), Abbott (US), Danaher Corporation (US), bioMérieux (France), and Thermo Fisher Scientific Inc. (US), among others, in the infectious disease diagnostics market.

Table of Contents

1               INTRODUCTION              39

1.1           STUDY OBJECTIVES       39

1.2           MARKET DEFINITION   39

1.3           MARKET SCOPE                40

1.3.1        MARKETS COVERED & REGIONAL SCOPE             40

1.3.2        INCLUSIONS & EXCLUSIONS       41

1.3.3        YEARS CONSIDERED      42

1.3.4        CURRENCY CONSIDERED            42

1.4           KEY STAKEHOLDERS     42

1.5           SUMMARY OF CHANGES               43

2               RESEARCH METHODOLOGY       44

2.1           RESEARCH DATA              44

2.2           RESEARCH APPROACH  44

2.2.1        SECONDARY DATA          45

2.2.1.1    Key secondary sources         45

2.2.1.2    Key data from secondary sources       46

2.2.2        PRIMARY DATA 47

2.2.2.1    Primary sources    47

2.2.2.2    Key data from primary sources           48

2.2.2.3    Key industry insights           49

2.2.2.4    Breakdown of primary interviews      50

2.3           MARKET SIZE ESTIMATION         50

2.3.1        BOTTOM-UP APPROACH              51

2.3.1.1    Approach 1: Company revenue estimation approach     51

2.3.1.2    Approach 2: Presentations of companies and primary interviews                 52

2.3.1.3    Growth forecast    52

2.3.1.4    CAGR projections                 52

2.3.2        TOP-DOWN APPROACH                53

2.4           MARKET BREAKDOWN AND DATA TRIANGULATION                 55

2.5           MARKET SHARE ASSESSMENT   55

2.6           RESEARCH ASSUMPTIONS           56

2.6.1        PARAMETRIC ASSUMPTIONS     56

2.7           RESEARCH LIMITATIONS             56

2.8           RISK ASSESSMENT           57

3               EXECUTIVE SUMMARY  58

4               PREMIUM INSIGHTS       64

4.1           INFECTIOUS DISEASE DIAGNOSTICS MARKET OVERVIEW          64

4.2           INFECTIOUS DISEASE DIAGNOSTICS MARKET,  BY PRODUCT & SERVICE,

2025 VS. 2030 (USD MILLION)      65

4.3           INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING,

2025 VS. 2030 (USD MILLION)      65

4.4           INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE,

2025 VS. 2030 (USD MILLION)      66

4.5           INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE,

2025 VS. 2030 (USD MILLION)      66

4.6           INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY,

2025 VS. 2030 (USD MILLION)      67

4.7           INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION,

2025 VS. 2030 (USD MILLION)      67

4.8           INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER,

2025 VS. 2030 (USD MILLION)      68

4.9           INFECTIOUS DISEASE DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES            68

5               MARKET OVERVIEW       69

5.1           INTRODUCTION              69

5.2           MARKET DYNAMICS       69

5.2.1        DRIVERS               70

5.2.1.1    Rising prevalence of infectious diseases            70

5.2.1.2    Rising focus on R&D and funding investments for infectious disease diagnostic products 71

5.2.1.3    Adoption of innovative & advanced technologies for infectious disease diagnosis  72

5.2.1.4    Gradual shift from centralized laboratories to decentralized PoC testing centers       73

5.2.2        RESTRAINTS      74

5.2.2.1    Unfavorable reimbursements              74

5.2.3        OPPORTUNITIES              74

5.2.3.1    High growth potential of emerging economies                74

5.2.4        CHALLENGES    76

5.2.4.1    Stringent regulatory guidelines for IVD products           76

5.2.4.2    Operational barriers and shortage of skilled laboratory technicians             76

5.3           PRICING ANALYSIS          77

5.3.1        INDICATIVE SELLING PRICE TREND OF INFECTIOUS DISEASE DIAGNOSTICS PRODUCTS, 2023−2025 77

5.3.2        INDICATIVE SELLING PRICE TREND OF INFECTIOUS DISEASE TEST KITS & ASSAYS, BY KEY PLAYER,2023−2025                 77

5.3.3        INDICATIVE SELLING PRICE TREND OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, BY REGION, 2023−2025                 78

5.4           PATENT ANALYSIS          79

5.4.1        LIST OF MAJOR PATENTS             80

5.5           VALUE CHAIN ANALYSIS               81

5.6           SUPPLY CHAIN ANALYSIS             82

5.7           TRADE ANALYSIS             83

5.7.1        TRADE ANALYSIS FOR DIAGNOSTIC & LABORATORY REAGENTS          83

5.7.2        IMPORT DATA (HS CODE 3822) 84

5.7.3        EXPORT DATA (HS CODE 3822) 84

5.8           ECOSYSTEM ANALYSIS  85

5.8.1        INFECTIOUS DISEASE DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM       85

5.9           PORTER’S FIVE FORCES ANALYSIS           86

5.9.1        THREAT OF NEW ENTRANTS      87

5.9.2        THREAT OF SUBSTITUTES          87

5.9.3        BARGAINING POWER OF BUYERS             87

5.9.4        BARGAINING POWER OF SUPPLIERS       87

5.9.5        INTENSITY OF COMPETITIVE RIVALRY 88

5.10         REGULATORY LANDSCAPE         88

5.10.1      REGULATORY FRAMEWORK       88

5.10.1.1  North America      88

5.10.1.1.1                US           88

5.10.1.1.2                Canada   88

5.10.1.2  Europe   88

5.10.1.2.1                Germany                 89

5.10.1.2.2                UK          89

5.10.1.2.3                France    90

5.10.1.2.4                Italy         90

5.10.1.3  Asia Pacific            90

5.10.1.3.1                China      90

5.10.1.3.2                Japan      90

5.10.1.3.3                India       91

5.10.1.4  Latin America       91

5.10.1.4.1                Brazil      91

5.10.1.4.2                Mexico   92

5.10.1.5  Middle East           92

5.10.1.5.1                Africa      92

5.10.2      REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS             92

5.11         TECHNOLOGY ANALYSIS             94

5.11.1      KEY TECHNOLOGIES     94

5.11.1.1  Immunodiagnostics              94

5.11.2      COMPLEMENTARY TECHNOLOGIES       95

5.11.2.1  Polymerase Chain Reaction (PCR)   95

5.11.3      ADJACENT TECHNOLOGIES       96

5.11.3.1  Next-generation Sequencing (NGS) 96

5.12         KEY CONFERENCES & EVENTS, 2025–2026              97

5.13         TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES       98

5.14         KEY STAKEHOLDERS & BUYING CRITERIA            98

5.14.1      KEY STAKEHOLDERS IN BUYING PROCESS           99

5.14.2      BUYING CRITERIA           99

5.15         INVESTMENT & FUNDING SCENARIO     100

5.16         CASE STUDY ANALYSIS 101

5.16.1      CASE STUDY 1: IMPLEMENTING RAPID PCR TESTING TO IMPROVE NOROVIRUS DIAGNOSIS & BED MANAGEMENT                 101

5.16.2      CASE STUDY 2: USING MOLECULAR DIAGNOSTICS TO IDENTIFY ATYPICAL RESPIRATORY INFECTIONS              101

5.16.3      CASE STUDY 3: RAPID DIFFERENTIATION OF VIRAL & BACTERIAL INFECTION IN PEDIATRIC PATIENTS             102

5.17         IMPACT OF AI/GENERATIVE AI ON INFECTIOUS DISEASE DIAGNOSTICS MARKET               102

5.17.1      INTRODUCTION              102

5.17.2      MARKET POTENTIAL OF AI         103

5.17.3      AI-USE CASES    103

5.17.4      IMPLEMENTATION OF AI, BY KEY COMPANY & CASE                 104

5.17.5      FUTURE OF AI IN INFECTIOUS DISEASE DIAGNOSTICS MARKET               104

5.18         TRUMP TARIFF IMPACT ON INFECTIOUS DISEASE DIAGNOSTICS MARKET 105

5.18.1      INTRODUCTION              105

5.18.2      KEY TARIFF RATES          105

5.18.3      PRICE IMPACT ANALYSIS             106

5.18.4      KEY IMPACT ON COUNTRY/REGION      106

5.18.4.1  North America      106

5.18.4.2  Europe   106

5.18.4.3  Asia Pacific            107

5.18.5      IMPACT ON END-USE INDUSTRIES          107

5.18.5.1  Diagnostic laboratories        107

5.18.5.2  Hospitals & clinics                107

5.18.5.3  Academic research institutes              107

6               INFECTIOUS DISEASE DIAGNOSTICS MARKET,  BY PRODUCT & SERVICE    108

6.1           INTRODUCTION              109

6.2           REAGENTS, KITS, AND CONSUMABLES  109

6.2.1        RECURRENT PURCHASE TO PROPEL MARKET   109

6.3           INSTRUMENTS 114

6.3.1        RAPID TECHNOLOGICAL ADVANCEMENTS FOR ADVANCED ACCURACY TO DRIVE MARKET        114

6.4           SOFTWARE & SERVICES 118

6.4.1        INCREASING FOCUS ON VALUE-ADDED SERVICES TO SUPPORT MARKET GROWTH     118

7               INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING       122

7.1           INTRODUCTION              123

7.2           LABORATORY TESTING                123

7.2.1        HIGHER SENSITIVITY & SPECIFICITY TO FUEL UPTAKE                 123

7.3           POC TESTING    126

7.3.1        RAPID TURNAROUND TIME AND INCREASING CLIA APPROVALS FOR POC TESTS TO PROPEL MARKET           126

8               INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE    130

8.1           INTRODUCTION              131

8.2           BLOOD, SERUM, AND PLASMA  131

8.2.1        HIGHER VERSATILITY, ENHANCED CLINICAL EFFICACY, AND IMPROVED REIMBURSEMENT POLICIES TO DRIVE MARKET               131

8.3           URINE   134

8.3.1        NON-INVASIVE NATURE AND ENHANCED PATIENT CONVENIENCE TO BOOST DEMAND      134

8.4           OTHER SAMPLE TYPES 137

9               INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE   140

9.1           INTRODUCTION              141

9.2           HEPATITIS          142

9.2.1        HEPATITIS B      146

9.2.1.1    Highly contagious infection and requirement for regular monitoring to fuel market   146

9.2.2        HEPATITIS C      149

9.2.2.1    Rising incidence of chronic HCV and supportive government initiatives to drive market   149

9.2.3        OTHER HEPATITIS DISEASES     151

9.3           HIV         154

9.3.1        INCREASING PREVALENCE OF AIDS TO BOOST DEMAND             154

9.4           HOSPITAL-ACQUIRED INFECTIONS        157

9.4.1        RISING BURDEN OF MRSA INFECTIONS TO FUEL MARKET               157

9.5           MOSQUITO-BORNE DISEASES   160

9.5.1        RISING INCIDENCE OF DENGUE & MALARIA TO PROPEL MARKET               160

9.6           HPV        164

9.6.1        RAPID TECHNOLOGICAL ADVANCES TO BOOST DEMAND             164

9.7           CHLAMYDIA TRACHOMATIS      166

9.7.1        INCREASING AWARENESS INITIATIVES TO SUPPORT MARKET UPTAKE             166

9.8           NEISSERIA GONORRHEA               169

9.8.1        RISING INCIDENCE OF GONORRHEA TO FUEL MARKET                 169

9.9           TUBERCULOSIS                172

9.9.1        INCREASING BURDEN OF TB IN UNDERSERVED AREAS TO DRIVE MARKET         172

9.10         INFLUENZA        175

9.10.1      INCREASING FOCUS ON RAPID DIAGNOSIS USING POC TESTING METHODS TO FUEL MARKET 175

9.11         SYPHILIS              178

9.11.1      IMPROVED SCREENING TECHNOLOGIES TO SUPPORT MARKET UPTAKE             178

9.12         OTHER INFECTIOUS DISEASES 181

10            INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY  184

10.1         INTRODUCTION              185

10.2         IMMUNODIAGNOSTICS                185

10.2.1      RISING PREVALENCE OF INFECTIOUS DISEASES AND DEMAND FOR RAPID DIAGNOSTIC KITS TO DRIVE MARKET                 185

10.3         CLINICAL MICROBIOLOGY          189

10.3.1      RAPID TURNAROUND TIME WITH HIGHER SENSITIVITY & RELIABLE RESULTS TO BOOST DEMAND         189

10.4         POLYMERASE CHAIN REACTION               192

10.4.1      CONVENIENCE & COST-EFFECTIVENESS TO FUEL UPTAKE                192

10.5         ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY  195

10.5.1      ENHANCED SUITABILITY FOR POC TESTING WITH LOW-COST FEATURES TO FUEL UPTAKE              195

10.6         DNA SEQUENCING & NEXT-GENERATION SEQUENCING                 197

10.6.1      ADVANCEMENTS IN SEQUENCING TECHNOLOGIES AND RISING FOCUS ON MOLECULAR TARGETED DRUGS TO PROPEL MARKET             197

10.7         DNA MICROARRAY          200

10.7.1      HIGH INSTRUMENT COSTS TO LIMIT MARKET 200

10.8         OTHER TECHNOLOGIES               203

11            INFECTIOUS DISEASE DIAGNOSTICS MARKET,  BY CLINICAL APPLICATION               206

11.1         INTRODUCTION              207

11.2         DIAGNOSTICS   207

11.2.1      INCREASING CLINICAL NEED FOR CONFIRMATORY TESTING & TIMELY TREATMENT TO DRIVE MARKET     207

11.3         SCREENING        210

11.3.1      GROWING IMPORTANCE OF EARLY DISEASE DETECTION TO FUEL MARKET 210

12            INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER     214

12.1         INTRODUCTION              215

12.2         DIAGNOSTIC LABORATORIES    215

12.2.1      ABILITY TO CATER TO HIGH-END SPECIALTY TESTING TO PROPEL MARKET      215

12.3         HOSPITALS & CLINICS   218

12.3.1      IMPROVED REIMBURSEMENTS AND CAPABILITY OF PURCHASING ADVANCED EQUIPMENT TO DRIVE MARKET                 218

12.4         ACADEMIC RESEARCH INSTITUTES        221

12.4.1      INCREASING R&D FUNDING INVESTMENTS TO FUEL MARKET               221

12.5         OTHER END USERS         224

13            INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION                227

13.1         INTRODUCTION              228

13.2         NORTH AMERICA             228

13.2.1      NORTH AMERICA: MACROECONOMIC OUTLOOK                 230

13.2.2      US           235

13.2.2.1  High healthcare expenditure to drive market  235

13.2.3      CANADA               239

13.2.3.1  Supportive government initiatives for infectious disease prevention to fuel market    239

13.3         EUROPE               243

13.3.1      EUROPE: MACROECONOMIC OUTLOOK               244

13.3.2      GERMANY           248

13.3.2.1  High adoption of advanced technologies to propel market                 248

13.3.3      UK          253

13.3.3.1  Increasing number of diagnostic centers to fuel uptake 253

13.3.4      FRANCE                257

13.3.4.1  Rising expenditure on life sciences R&D to drive market                 257

13.3.5      ITALY    261

13.3.5.1  Rising incidence of chronic diseases to boost demand   261

13.3.6      SPAIN    265

13.3.6.1  High prevalence of HIV and consolidation of diagnostic laboratories to drive market                265

13.3.7      REST OF EUROPE             269

13.4         ASIA PACIFIC     273

13.4.1      ASIA PACIFIC: MACROECONOMIC OUTLOOK     274

13.4.2      CHINA  279

13.4.2.1  Increasing burden of hepatitis B virus cases and growing government focus on health surveillance to drive market              279

13.4.3      JAPAN   283

13.4.3.1  Presence of established healthcare system and universal reimbursement policies to fuel uptake               283

13.4.4      INDIA    288

13.4.4.1  High prevalence of TB & HIV to propel market              288

13.4.5      REST OF ASIA PACIFIC   292

13.5         LATIN AMERICA                297

13.5.1      LATIN AMERICA: MACROECONOMIC OUTLOOK                 298

13.5.2      BRAZIL 302

13.5.2.1  Rising focus on initiating public-private investments for healthcare improvement to fuel uptake             302

13.5.3      MEXICO                306

13.5.3.1  Improving accessibility & affordability of healthcare services to support market growth        306

13.5.4      REST OF LATIN AMERICA             310

13.6         MIDDLE EAST & AFRICA                314

13.6.1      MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK                 315

13.6.2      KINGDOM OF SAUDI ARABIA (KSA)         319

13.6.2.1  Integration of digital health systems and improvements in healthcare infrastructure to fuel market            319

13.6.3      UNITED ARAB EMIRATES (UAE)                323

13.6.3.1  Rising requirement of high-quality healthcare services to support market growth       323

13.6.4      REST OF MIDDLE EAST & AFRICA             327

14            COMPETITIVE LANDSCAPE         332

14.1         INTRODUCTION              332

14.2         KEY PLAYER STRATEGIES/RIGHT TO WIN            332

14.2.1      OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN INFECTIOUS DISEASE DIAGNOSTICS MARKET   332

14.3         REVENUE SHARE ANALYSIS, 2022−2024  334

14.4         MARKET SHARE ANALYSIS, 2024                 335

14.5         COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024                 337

14.5.1      STARS   337

14.5.2      EMERGING LEADERS     337

14.5.3      PERVASIVE PLAYERS      337

14.5.4      PARTICIPANTS 337

14.5.5      COMPANY FOOTPRINT: KEY PLAYERS, 2024         339

14.5.5.1  Company footprint               339

14.5.5.2  Region footprint   339

14.5.5.3  Product & Service footprint                 340

14.5.5.4  Type of testing footprint     340

14.5.5.5  Sample type footprint           341

14.6         COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024        341

14.6.1      PROGRESSIVE COMPANIES         341

14.6.2      RESPONSIVE COMPANIES            341

14.6.3      DYNAMIC COMPANIES  341

14.6.4      STARTING BLOCKS         342

14.6.5      COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024        343

14.6.5.1  Detailed list of key startups/SMEs    343

14.6.5.2  Competitive benchmarking of startups/SMEs (1/2)      343

14.6.5.3  Competitive benchmarking of startups/SMEs (2/2)      344

14.7         COMPANY VALUATION & FINANCIAL METRICS 344

14.7.1      FINANCIAL METRICS      344

14.7.2      COMPANY VALUATION 345

14.8         BRAND/PRODUCT COMPARISON             346

14.8.1      BRAND/PRODUCT COMPARATIVE ANALYSIS     346

14.9         COMPETITIVE SCENARIO             346

14.9.1      PRODUCT/SERVICES LAUNCHES & APPROVALS                 346

14.9.2      DEALS  347

14.9.3      EXPANSIONS     348

15            COMPANY PROFILES      349

15.1         KEY PLAYERS     349

15.1.1      F. HOFFMANN-LA ROCHE LTD. 349

15.1.1.1  Business overview 349

15.1.1.2  Products/Services offered   350

15.1.1.3  Recent developments           353

15.1.1.3.1                Product/Service launches & approvals              353

15.1.1.3.2                Deals      355

15.1.1.3.3                Expansions             355

15.1.1.4  MnM view              356

15.1.1.4.1                Key strengths        356

15.1.1.4.2                Strategic choices   356

15.1.1.4.3                Weaknesses & competitive threats     356

15.1.2      ABBOTT               357

15.1.2.1  Business overview 357

15.1.2.2  Products/Services offered   358

15.1.2.3  Recent developments           360

15.1.2.3.1                Product/Service launches & approvals              360

15.1.2.3.2                Deals      361

15.1.2.4  MnM view              361

15.1.2.4.1                Key strengths        361

15.1.2.4.2                Strategic choices   361

15.1.2.4.3                Weaknesses & competitive threats     361

15.1.3      DANAHER CORPORATION           362

15.1.3.1  Business overview 362

15.1.3.2  Products/Services offered   363

15.1.3.3  Recent developments           365

15.1.3.3.1                Product/Service launches & approvals              365

15.1.3.3.2                Deals      366

15.1.3.3.3                Expansions             367

15.1.3.4  MnM view              367

15.1.3.4.1                Key strengths        367

15.1.3.4.2                Strategic choices   367

15.1.3.4.3                Weaknesses & competitive threats     367

15.1.4      BIOMÉRIEUX     368

15.1.4.1  Business overview 368

15.1.4.2  Products/Services offered   369

15.1.4.3  Recent developments           373

15.1.4.3.1                Product/Service launches & approvals              373

15.1.4.3.2                Deals      375

15.1.4.4  MnM view              376

15.1.4.4.1                Key strengths        376

15.1.4.4.2                Strategic choices   376

15.1.4.4.3                Weaknesses & competitive threats     376

15.1.5      THERMO FISHER SCIENTIFIC INC.            377

15.1.5.1  Business overview 377

15.1.5.2  Products/Services offered   378

15.1.5.3  Recent developments           380

15.1.5.3.1                Product/Service launches & approvals              380

15.1.5.3.2                Deals      381

15.1.5.4  MnM view              382

15.1.5.4.1                Key strengths        382

15.1.5.4.2                Strategic choices   382

15.1.5.4.3                Weaknesses & competitive threats     382

15.1.6      SIEMENS HEALTHINEERS AG      383

15.1.6.1  Business overview 383

15.1.6.2  Products/Services offered   384

15.1.6.3  Recent developments           386

15.1.6.3.1                Product/Service launches & approvals              386

15.1.6.3.2                Deals      386

15.1.6.3.3                Expansions             387

15.1.7      HOLOGIC, INC. 388

15.1.7.1  Business overview 388

15.1.7.2  Products/Services offered   389

15.1.7.3  Recent developments           390

15.1.7.3.1                Product/Service launches & approvals              390

15.1.7.3.2                Deals      391

15.1.8      BECTON, DICKINSON AND COMPANY (BD)         392

15.1.8.1  Business overview 392

15.1.8.2  Products/Services offered   393

15.1.8.3  Recent developments           396

15.1.8.3.1                Product/Service launches & approvals              396

15.1.8.3.2                Deals      397

15.1.8.3.3                Expansions             398

15.1.9      REVVITY, INC.   399

15.1.9.1  Business overview 399

15.1.9.2  Products/Services offered   400

15.1.9.3  Recent developments           402

15.1.9.3.1                Product/Service launches & approvals              402

15.1.10   QIAGEN N.V.      403

15.1.10.1                 Business overview 403

15.1.10.2                 Products/Services offered   404

15.1.10.3                 Recent developments           406

15.1.10.3.1             Product/Service launches & approvals              406

15.1.10.3.2             Deals      408

15.1.10.3.3             Expansions             408

15.1.11   SEEGENE INC.   409

15.1.11.1                 Business overview 409

15.1.11.2                 Products/Services offered   410

15.1.11.3                 Recent developments           411

15.1.11.3.1             Product/Service launches & approvals              411

15.1.11.3.2             Deals      412

15.1.11.3.3             Expansions             413

15.2         OTHER PLAYERS              414

15.2.1      QUIDELORTHO CORPORATION                414

15.2.2      GRIFOLS, S.A.     416

15.2.3      DIASORIN S.P.A 417

15.2.4      BIO-RAD LABORATORIES, INC.  419

15.2.5      SYSMEX CORPORATION                421

15.2.6      ORASURE TECHNOLOGIES, INC.               422

15.2.7      CO-DIAGNOSTICS, INC. 423

15.2.8      SD BIOSENSOR, INC.       424

15.2.9      BIOSYNEX SA     425

15.2.10   TRINITY BIOTECH           427

15.2.11   BRUKER (ELITECHGROUP)          428

15.2.12   GENETIC SIGNATURES 430

15.2.13   EPITOPE DIAGNOSTICS, INC.     430

15.2.14   TRIVITRON HEALTHCARE           431

15.2.15   MERIL LIFE SCIENCES PVT. LTD.               432

15.2.16   INBIOS INTERNATIONAL, INC.  433

15.2.17   UNIOGEN OY     434

15.2.18   VELA DIAGNOSTICS       435

15.2.19   MOLBIO DIAGNOSTICS LIMITED              436

16            APPENDIX           438

16.1         DISCUSSION GUIDE        438

16.2         KNOWLEDGESTORE: MARKETSANDMARKETS’  SUBSCRIPTION PORTAL                443

16.3         CUSTOMIZATION OPTIONS        445

16.4         RELATED REPORTS         445

16.5         AUTHOR DETAILS           446

LIST OF TABLES

TABLE 1                INFECTIOUS DISEASE DIAGNOSTICS MARKET: INCLUSIONS & EXCLUSIONS       41

TABLE 2                INFECTIOUS DISEASE DIAGNOSTICS MARKET: KEY DATA FROM PRIMARY SOURCES     48

TABLE 3                INFECTIOUS DISEASE DIAGNOSTICS MARKET: RISK ASSESSMENT ANALYSIS      57

TABLE 4                REGIONAL HIV DATA, 2024          71

TABLE 5                INDICATIVE SELLING PRICING TREND OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, 2023–2025                 77

TABLE 6                INDICATIVE SELLING PRICE TREND OF INFECTIOUS DISEASE TEST KITS & ASSAYS, BY KEY PLAYER, 2023–2025              77

TABLE 7                INDICATIVE SELLING PRICE TREND OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, BY REGION, 2023–2025              78

TABLE 8                INFECTIOUS DISEASE DIAGNOSTICS MARKET: LIST OF MAJOR PATENTS             80

TABLE 9                IMPORT DATA FOR DIAGNOSTIC & LABORATORY REAGENTS (HS CODE 3822),

BY COUNTRY, 2020–2024 (USD MILLION)               84

TABLE 10              EXPORT DATA FOR DIAGNOSTIC & LABORATORY REAGENTS (HS CODE 3822),

BY COUNTRY, 2020–2024 (USD MILLION)               84

TABLE 11              INFECTIOUS DISEASE DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM     85

TABLE 12              INFECTIOUS DISEASE DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS           87

TABLE 13              CLASSIFICATION OF IVD DEVICES IN EUROPE                 89

TABLE 14              TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS IN JAPAN         91

TABLE 17              ASIA PACIFIC: LIST OF KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS             93

TABLE 20              INFECTIOUS DISEASE DIAGNOSTICS MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026     97

TABLE 21              INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS (%)         99

TABLE 22              KEY BUYING CRITERIA FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS,

BY RANK               100

TABLE 23              IMPLEMENTATION OF AI, BY KEY COMPANY & CASE      104

TABLE 24              US-ADJUSTED RECIPROCAL TARIFF RATES                 105

TABLE 25              INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,

2023–2030 (USD MILLION)T         109

TABLE 26              KEY REAGENTS, KITS, AND CONSUMABLES CURRENTLY AVAILABLE               111

TABLE 27              INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY REGION, 2023–2030 (USD MILLION)       112

TABLE 28              NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION)                 112

TABLE 29              EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION)     112

TABLE 30              ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION)                 113

TABLE 31              LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION)                 113

TABLE 32              MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION)                 113

TABLE 33              KEY INSTRUMENTS CURRENTLY AVAILABLE                 115

TABLE 34              INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION,  2023–2030 (USD MILLION)                 116

TABLE 35              NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS,  BY COUNTRY, 2023–2030 (USD MILLION)            116

TABLE 36              EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS,

BY COUNTRY, 2023–2030 (USD MILLION)               116

TABLE 37              ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS,  BY COUNTRY, 2023–2030 (USD MILLION)            117

TABLE 38              LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS,  BY COUNTRY, 2023–2030 (USD MILLION)            117

TABLE 39              MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION)            117

TABLE 40              KEY SOFTWARE & SERVICES CURRENTLY AVAILABLE         118

TABLE 41              INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES,

BY REGION, 2023–2030 (USD MILLION)   119

TABLE 42              NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)     119

TABLE 43              EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES,  BY COUNTRY, 2023–2030 (USD MILLION) 120

TABLE 44              ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)     120

TABLE 45              LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)     120

TABLE 46              MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)     121

TABLE 47              INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING,

2023–2030 (USD MILLION)            123

TABLE 48              KEY LABORATORY TEST TYPES CURRENTLY AVAILABLE         124

TABLE 49              INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING,

BY REGION, 2023–2030 (USD MILLION)   124

TABLE 50              NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY COUNTRY, 2023–2030 (USD MILLION)     125

TABLE 51              EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING,  BY COUNTRY, 2023–2030 (USD MILLION)       125

TABLE 52              ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY COUNTRY, 2023–2030 (USD MILLION)     125

TABLE 53              LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY COUNTRY, 2023–2030 (USD MILLION)     126

TABLE 54              MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY COUNTRY, 2023–2030 (USD MILLION)     126

TABLE 55              KEY POC TESTING TYPES CURRENTLY AVAILABLE         127

TABLE 56              INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY REGION,  2023–2030 (USD MILLION)                 127

TABLE 57              NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING,  BY COUNTRY, 2023–2030 (USD MILLION)            128

TABLE 58              EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING,

BY COUNTRY, 2023–2030 (USD MILLION)               128

TABLE 59              ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING,

BY COUNTRY, 2023–2030 (USD MILLION)               128

TABLE 60              LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING,  BY COUNTRY, 2023–2030 (USD MILLION)            129

TABLE 61              MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY COUNTRY, 2023–2030 (USD MILLION)       129

TABLE 62              INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE,

2023–2030 (USD MILLION)            131

TABLE 63              INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY REGION, 2023–2030 (USD MILLION)       132

TABLE 64              NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)          132

TABLE 65              EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)     133

TABLE 66              ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)          133

TABLE 67              LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)          133

TABLE 68              MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)          134

TABLE 69              INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY REGION,  2023–2030 (USD MILLION)                 135

TABLE 70              NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE SAMPLES,  BY COUNTRY, 2023–2030 (USD MILLION)            135

TABLE 71              EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE SAMPLES,

BY COUNTRY, 2023–2030 (USD MILLION)               135

TABLE 72              ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE SAMPLES,  BY COUNTRY, 2023–2030 (USD MILLION)            136

TABLE 73              LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE SAMPLES,  BY COUNTRY, 2023–2030 (USD MILLION)            136

TABLE 74              MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)            136

TABLE 75              INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES,

BY REGION, 2023–2030 (USD MILLION)   137

TABLE 76              NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION)     137

TABLE 77              EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES,  BY COUNTRY, 2023–2030 (USD MILLION) 138

TABLE 78              ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION)     138

TABLE 79              LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION)     138

TABLE 80              MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION)     139

TABLE 81              INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE,

2023–2030 (USD MILLION)            141

TABLE 82              KEY HEPATITIS TESTING PRODUCTS CURRENTLY AVAILABLE               143

TABLE 83              INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION,

2023–2030 (USD MILLION)            144

TABLE 84              NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS,

BY COUNTRY, 2023–2030 (USD MILLION)               144

TABLE 85              EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS,

BY COUNTRY, 2023–2030 (USD MILLION)               144

TABLE 86              ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS,

BY COUNTRY, 2023–2030 (USD MILLION)               145

TABLE 87              LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS,

BY COUNTRY, 2023–2030 (USD MILLION)               145

TABLE 88              MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS,  BY COUNTRY, 2023–2030 (USD MILLION)       145

TABLE 89              INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE,

2023–2030 (USD MILLION)            146

TABLE 90              INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS B, BY REGION,  2023–2030 (USD MILLION)                 147

TABLE 91              NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS B,  BY COUNTRY, 2023–2030 (USD MILLION)       147

TABLE 92              EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS B,

BY COUNTRY, 2023–2030 (USD MILLION)               147

TABLE 93              ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS B,

BY COUNTRY, 2023–2030 (USD MILLION)               148

TABLE 94              LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS B,  BY COUNTRY, 2023–2030 (USD MILLION)       148

TABLE 95              MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY, 2023–2030 (USD MILLION)       148

TABLE 96              INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS C, BY REGION,  2023–2030 (USD MILLION)                 149

TABLE 97              NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS C,  BY COUNTRY, 2023–2030 (USD MILLION)       150

TABLE 98              EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS C,

BY COUNTRY, 2023–2030 (USD MILLION)               150

TABLE 99              ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS C,

BY COUNTRY, 2023–2030 (USD MILLION)               150

TABLE 100            LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS C,  BY COUNTRY, 2023–2030 (USD MILLION)       151

TABLE 101            MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY, 2023–2030 (USD MILLION)       151

TABLE 102            INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES,

BY REGION, 2023–2030 (USD MILLION)   152

TABLE 103            NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)     152

TABLE 104            EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)       153

TABLE 105            ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)     153

TABLE 106            LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)     153

TABLE 107            MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)     154

TABLE 108            KEY HIV TESTING PRODUCTS CURRENTLY AVAILABLE         154

TABLE 109            INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY REGION,

2023–2030 (USD MILLION)            155

TABLE 110            NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV,

BY COUNTRY, 2023–2030 (USD MILLION)               155

TABLE 111            EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY COUNTRY,  2023–2030 (USD MILLION)                 156

TABLE 112            ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2023–2030 (USD MILLION)            156

TABLE 113            LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV,

BY COUNTRY, 2023–2030 (USD MILLION)               156

TABLE 114            MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV,

BY COUNTRY, 2023–2030 (USD MILLION)               157

TABLE 115            KEY HAI TESTING PRODUCTS CURRENTLY AVAILABLE         158

TABLE 116            INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS,  BY REGION, 2023–2030 (USD MILLION)       158

TABLE 117            NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023–2030 (USD MILLION)   158

TABLE 118            EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023–2030 (USD MILLION)            159

TABLE 119            ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023–2030 (USD MILLION)   159

TABLE 120            LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023–2030 (USD MILLION)   159

TABLE 121            MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023–2030 (USD MILLION)   160

TABLE 122            KEY DENGUE-TESTING PRODUCTS CURRENTLY AVAILABLE               161

TABLE 123            INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES,  BY REGION, 2023–2030 (USD MILLION) 162

TABLE 124            NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)     162

TABLE 125            EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, 2023–2030 (USD MILLION)            162

TABLE 126            ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)     163

TABLE 127            LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)     163

TABLE 128            MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)     163

TABLE 129            KEY HPV TESTING PRODUCTS CURRENTLY AVAILABLE         164

TABLE 130            INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY REGION,

2023–2030 (USD MILLION)            164

TABLE 131            NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV,

BY COUNTRY, 2023–2030 (USD MILLION)               165

TABLE 132            EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY COUNTRY,  2023–2030 (USD MILLION)                 165

TABLE 133            ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2023–2030 (USD MILLION)            165

TABLE 134            LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV,

BY COUNTRY, 2023–2030 (USD MILLION)               166

TABLE 135            MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV,  BY COUNTRY, 2023–2030 (USD MILLION) 166

TABLE 136            KEY CHLAMYDIA TRACHOMATIS TESTING PRODUCTS CURRENTLY AVAILABLE      167

TABLE 137            INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS,

BY REGION, 2023–2030 (USD MILLION)   167

TABLE 138            NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2023–2030 (USD MILLION)     167

TABLE 139            EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2023–2030 (USD MILLION)       168

TABLE 140            ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2023–2030 (USD MILLION)     168

TABLE 141            LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2023–2030 (USD MILLION)     168

TABLE 142            MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2023–2030 (USD MILLION)     169

TABLE 143            INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHOEAE,

BY REGION, 2023–2030 (USD MILLION)   170

TABLE 144            NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2023–2030 (USD MILLION)     170

TABLE 145            EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2023–2030 (USD MILLION)       170

TABLE 146            ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2023–2030 (USD MILLION)     171

TABLE 147            LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2023–2030 (USD MILLION)     171

TABLE 148            MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2023–2030 (USD MILLION)     171

TABLE 149            KEY TUBERCULOSIS TESTING PRODUCTS CURRENTLY AVAILABLE               173

TABLE 150            GLOBAL NUMBER OF NEWLY DIAGNOSED TUBERCULOSIS (TB) CASES,

2023–2030 (IN MILLIONS)              173

TABLE 151            INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY REGION,  2023–2030 (USD MILLION)                 173

TABLE 152            NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS,  BY COUNTRY, 2023–2030 (USD MILLION)            174

TABLE 153            EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS,

BY COUNTRY, 2023–2030 (USD MILLION)               174

TABLE 154            ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS,  BY COUNTRY, 2023–2030 (USD MILLION)            174

TABLE 155            LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS,  BY COUNTRY, 2023–2030 (USD MILLION)            175

TABLE 156            MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2023–2030 (USD MILLION)            175

TABLE 157            KEY INFLUENZA TESTING PRODUCTS CURRENTLY AVAILABLE               176

TABLE 158            INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY REGION,

2023–2030 (USD MILLION)            176

TABLE 159            NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA,  BY COUNTRY, 2023–2030 (USD MILLION)       177

TABLE 160            EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA,

BY COUNTRY, 2023–2030 (USD MILLION)               177

TABLE 161            ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA,

BY COUNTRY, 2023–2030 (USD MILLION)               177

TABLE 162            LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA,

BY COUNTRY, 2023–2030 (USD MILLION)               178

TABLE 163            MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY, 2023–2030 (USD MILLION)       178

TABLE 164            KEY SYPHILIS TESTING PRODUCTS CURRENTLY AVAILABLE         179

TABLE 165            INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY REGION,

2023–2030 (USD MILLION)            179

TABLE 166            NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS,

BY COUNTRY, 2023–2030 (USD MILLION)               179

TABLE 167            EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS,

BY COUNTRY, 2023–2030 (USD MILLION)               180

TABLE 168            ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS,

BY COUNTRY, 2023–2030 (USD MILLION)               180

TABLE 169            LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS,

BY COUNTRY, 2023–2030 (USD MILLION)               180

TABLE 170            MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS,  BY COUNTRY, 2023–2030 (USD MILLION)       181

TABLE 171            INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES,  BY REGION, 2023–2030 (USD MILLION) 182

TABLE 172            NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)     182

TABLE 173            EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)            182

TABLE 174            ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)     183

TABLE 175            LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)     183

TABLE 176            MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)     183

TABLE 177            INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            185

TABLE 178            KEY IMMUNODIAGNOSTICS-BASED PRODUCTS CURRENTLY AVAILABLE               186

TABLE 179            INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS,

BY REGION, 2023–2030 (USD MILLION)   187

TABLE 180            NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)     187

TABLE 181            EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS,  BY COUNTRY, 2023–2030 (USD MILLION)       187

TABLE 182            ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)     188

TABLE 183            LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)     188

TABLE 184            MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)     188

TABLE 185            KEY CLINICAL MICROBIOLOGY-BASED PRODUCTS CURRENTLY AVAILABLE      189

TABLE 186            INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY,

BY REGION, 2023–2030 (USD MILLION)   190

TABLE 187            NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)     190

TABLE 188            EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY,  BY COUNTRY, 2023–2030 (USD MILLION)       190

TABLE 189            ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)     191

TABLE 190            LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)     191

TABLE 191            MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)     191

TABLE 192            KEY POLYMERASE CHAIN REACTION-BASED PRODUCTS CURRENTLY AVAILABLE      192

TABLE 193            INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION,  BY REGION, 2023–2030 (USD MILLION) 193

TABLE 194            NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)               193

TABLE 195            EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)            193

TABLE 196            ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)               194

TABLE 197            LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)               194

TABLE 198            MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)               194

TABLE 199            KEY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY-BASED PRODUCTS CURRENTLY AVAILABLE               195

TABLE 200            INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2023–2030 (USD MILLION)   195

TABLE 201            NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            196

TABLE 202            EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)                 196

TABLE 203            ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            196

TABLE 204            LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            197

TABLE 205            MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            197

TABLE 206            KEY DNA SEQUENCING & NEXT-GENERATION SEQUENCING-BASED PRODUCTS CURRENTLY AVAILABLE                 198

TABLE 207            INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2023–2030 (USD MILLION)          198

TABLE 208            NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY,

2023–2030 (USD MILLION)            199

TABLE 209            EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, 2023–2030 (USD MILLION)              199

TABLE 210            ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)            199

TABLE 211            LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY,

2023–2030 (USD MILLION)            200

TABLE 212            MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY,

2023–2030 (USD MILLION)            200

TABLE 213            KEY DNA MICROARRAY-BASED PRODUCTS CURRENTLY AVAILABLE               201

TABLE 214            INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY REGION, 2023–2030 (USD MILLION)                 201

TABLE 215            NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION)            201

TABLE 216            EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS,  BY COUNTRY, 2023–2030 (USD MILLION) 202

TABLE 217            ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS,  BY COUNTRY, 2023–2030 (USD MILLION)     202

TABLE 218            LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION)            202

TABLE 219            MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION)            203

TABLE 220            INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES,

BY REGION, 2023–2030 (USD MILLION)   204

TABLE 221            NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)     204

TABLE 222            EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES,  BY COUNTRY, 2023–2030 (USD MILLION)       204

TABLE 223            ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)     205

TABLE 224            LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)     205

TABLE 225            MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)     205

TABLE 226            INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION,

2023–2030 (USD MILLION)            207

TABLE 227            KEY DIAGNOSTICS PRODUCTS CURRENTLY AVAILABLE         208

TABLE 228            INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTICS, BY REGION,  2023–2030 (USD MILLION)                 208

TABLE 229            NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTICS,  BY COUNTRY, 2023–2030 (USD MILLION)            209

TABLE 230            EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTICS,

BY COUNTRY, 2023–2030 (USD MILLION)               209

TABLE 231            ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTICS,

BY COUNTRY, 2023–2030 (USD MILLION)               209

TABLE 232            LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTICS,  BY COUNTRY, 2023–2030 (USD MILLION)            210

TABLE 233            MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)       210

TABLE 234            KEY SCREENING PRODUCTS CURRENTLY AVAILABLE         211

TABLE 235            INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SCREENING, BY REGION,  2023–2030 (USD MILLION)                 211

TABLE 236            NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SCREENING,  BY COUNTRY, 2023–2030 (USD MILLION)       211

TABLE 237            EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SCREENING,

BY COUNTRY, 2023–2030 (USD MILLION)               212

TABLE 238            ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SCREENING,

BY COUNTRY, 2023–2030 (USD MILLION)               212

TABLE 239            LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SCREENING,  BY COUNTRY, 2023–2030 (USD MILLION)       212

TABLE 240            MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY, 2023–2030 (USD MILLION)       213

TABLE 241            INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER,

2023–2030 (USD MILLION)            215

TABLE 242            INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES,  BY REGION, 2023–2030 (USD MILLION) 216

TABLE 243            NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)     216

TABLE 244            EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)            217

TABLE 245            ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)     217

TABLE 246            LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)     217

TABLE 247            MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)     218

TABLE 248            INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS,

BY REGION, 2023–2030 (USD MILLION)   219

TABLE 249            NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)     219

TABLE 250            EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS,  BY COUNTRY, 2023–2030 (USD MILLION) 220

TABLE 251            ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)     220

TABLE 252            LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)     220

TABLE 253            MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)     221

TABLE 254            INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES,  BY REGION, 2023–2030 (USD MILLION)       222

TABLE 255            NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)               222

TABLE 256            EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)            222

TABLE 257            ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)               223

TABLE 258            LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)               223

TABLE 259            MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)               223

TABLE 260            INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION,  2023–2030 (USD MILLION)            224

TABLE 261            NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)            225

TABLE 262            EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS,  BY COUNTRY, 2023–2030 (USD MILLION) 225

TABLE 263            ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS,  BY COUNTRY, 2023–2030 (USD MILLION)            225

TABLE 264            LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)            226

TABLE 265            MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)            226

TABLE 266            INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION,

2023–2030 (USD MILLION)            228

TABLE 267            NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY,  2023–2030 (USD MILLION)            231

TABLE 268            NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 231

TABLE 269            NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION)            231

TABLE 270            NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE,  2023–2030 (USD MILLION)            232

TABLE 271            NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)            232

TABLE 272            NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS,

BY TYPE, 2023–2030 (USD MILLION)         233

TABLE 273            NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY,  2023–2030 (USD MILLION)            233

TABLE 274            NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 234

TABLE 275            NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER,  2023–2030 (USD MILLION)            234

TABLE 276            NORTH AMERICA: MACROECONOMIC INDICATORS      234

TABLE 277            US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,  2023–2030 (USD MILLION)                 236

TABLE 278            US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING,

2023–2030 (USD MILLION)            236

TABLE 279            US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE,

2023–2030 (USD MILLION)            236

TABLE 280            US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE,

2023–2030 (USD MILLION)            237

TABLE 281            US: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE,

2023–2030 (USD MILLION)            237

TABLE 282            US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            238

TABLE 283            US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)                 238

TABLE 284            US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER,

2023–2030 (USD MILLION)            239

TABLE 285            CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,  2023–2030 (USD MILLION)                 240

TABLE 286            CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING,  2023–2030 (USD MILLION)                 240

TABLE 287            CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE,

2023–2030 (USD MILLION)            241

TABLE 288            CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE,

2023–2030 (USD MILLION)            241

TABLE 289            CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE,  2023–2030 (USD MILLION)                 242

TABLE 290            CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            242

TABLE 291            CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)                 243

TABLE 292            CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER,

2023–2030 (USD MILLION)            243

TABLE 293            EUROPE: MACROECONOMIC INDICATORS                 244

TABLE 294            EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            245

TABLE 295            EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,  2023–2030 (USD MILLION)                 245

TABLE 296            EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING,  2023–2030 (USD MILLION)                 245

TABLE 297            EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE,

2023–2030 (USD MILLION)            246

TABLE 298            EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE,

2023–2030 (USD MILLION)            246

TABLE 299            EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE,  2023–2030 (USD MILLION)                 247

TABLE 300            EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            247

TABLE 301            EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)                 248

TABLE 302            EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER,

2023–2030 (USD MILLION)            248

TABLE 303            GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)                 249

TABLE 304            GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING,  2023–2030 (USD MILLION)                 250

TABLE 305            GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE,  2023–2030 (USD MILLION) 250

TABLE 306            GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE,  2023–2030 (USD MILLION)                 251

TABLE 307            GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE,  2023–2030 (USD MILLION)                 251

TABLE 308            GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY,  2023–2030 (USD MILLION)                 252

TABLE 309            GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)                 252

TABLE 310            GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER,

2023–2030 (USD MILLION)            253

TABLE 311            UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,  2023–2030 (USD MILLION)                 254

TABLE 312            UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING,

2023–2030 (USD MILLION)            254

TABLE 313            UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE,

2023–2030 (USD MILLION)            255

TABLE 314            UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE,

2023–2030 (USD MILLION)            255

TABLE 315            UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE,

2023–2030 (USD MILLION)            256

TABLE 316            UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            256

TABLE 317            UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION,  2023–2030 (USD MILLION)            256

TABLE 318            UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER,

2023–2030 (USD MILLION)            257

TABLE 319            FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,  2023–2030 (USD MILLION)                 258

TABLE 320            FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING,  2023–2030 (USD MILLION)                 258

TABLE 321            FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE,

2023–2030 (USD MILLION)            258

TABLE 322            FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE,

2023–2030 (USD MILLION)            259

TABLE 323            FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE,  2023–2030 (USD MILLION)                 259

TABLE 324            FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            260

TABLE 325            FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)                 260

TABLE 326            FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER,

2023–2030 (USD MILLION)            261

TABLE 327            ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,  2023–2030 (USD MILLION)                 262

TABLE 328            ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING,

2023–2030 (USD MILLION)            262

TABLE 329            ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE,

2023–2030 (USD MILLION)            262

TABLE 330            ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE,

2023–2030 (USD MILLION)            263

TABLE 331            ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE,  2023–2030 (USD MILLION)                 263

TABLE 332            ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            264

TABLE 333            ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION,  2023–2030 (USD MILLION)            264

TABLE 334            ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER,

2023–2030 (USD MILLION)            265

TABLE 335            SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,  2023–2030 (USD MILLION)                 266

TABLE 336            SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING,

2023–2030 (USD MILLION)            266

TABLE 337            SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE,

2023–2030 (USD MILLION)            266

TABLE 338            SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE,

2023–2030 (USD MILLION)            267

TABLE 339            SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE,  2023–2030 (USD MILLION)                 267

TABLE 340            SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            268

TABLE 341            SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION,  2023–2030 (USD MILLION)            268

TABLE 342            SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER,

2023–2030 (USD MILLION)            269

TABLE 343            GDP EXPENDITURE ON HEALTHCARE, BY COUNTRY (%)   269

TABLE 344            REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 270

TABLE 345            REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION)            270

TABLE 346            REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE,  2023–2030 (USD MILLION)            270

TABLE 347            REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)            271

TABLE 348            REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS,

BY TYPE, 2023–2030 (USD MILLION)         271

TABLE 349            REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY,  2023–2030 (USD MILLION)            272

TABLE 350            REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 272

TABLE 351            REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER,  2023–2030 (USD MILLION)            273

TABLE 352            ASIA PACIFIC: MACROECONOMIC INDICATORS                 275

TABLE 353            ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            275

TABLE 354            ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 275

TABLE 355            ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING,  2023–2030 (USD MILLION)            276

TABLE 356            ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE,  2023–2030 (USD MILLION)            276

TABLE 357            ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE,  2023–2030 (USD MILLION)            277

TABLE 358            ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS,

BY TYPE, 2023–2030 (USD MILLION)         277

TABLE 359            ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY,  2023–2030 (USD MILLION)            278

TABLE 360            ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 278

TABLE 361            ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER,

2023–2030 (USD MILLION)            279

TABLE 362            CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,  2023–2030 (USD MILLION)                 280

TABLE 363            CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING,

2023–2030 (USD MILLION)            280

TABLE 364            CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE,

2023–2030 (USD MILLION)            281

TABLE 365            CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE,

2023–2030 (USD MILLION)            281

TABLE 366            CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE,  2023–2030 (USD MILLION)                 282

TABLE 367            CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            282

TABLE 368            CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION,  2023–2030 (USD MILLION)            283

TABLE 369            CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER,

2023–2030 (USD MILLION)            283

TABLE 370            JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,  2023–2030 (USD MILLION)                 284

TABLE 371            JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING,

2023–2030 (USD MILLION)            285

TABLE 372            JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE,

2023–2030 (USD MILLION)            285

TABLE 373            JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE,

2023–2030 (USD MILLION)            286

TABLE 374            JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE,  2023–2030 (USD MILLION)                 286

TABLE 375            JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            287

TABLE 376            JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION,  2023–2030 (USD MILLION)            287

TABLE 377            JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER,

2023–2030 (USD MILLION)            288

TABLE 378            INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,  2023–2030 (USD MILLION)                 289

TABLE 379            INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING,

2023–2030 (USD MILLION)            289

TABLE 380            INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE,

2023–2030 (USD MILLION)            290

TABLE 381            INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE,

2023–2030 (USD MILLION)            290

TABLE 382            INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE,  2023–2030 (USD MILLION)                 291

TABLE 383            INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            291

TABLE 384            INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION,  2023–2030 (USD MILLION)            292

TABLE 385            INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER,

2023–2030 (USD MILLION)            292

TABLE 386            REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 293

TABLE 387            REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION)            294

TABLE 388            REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)            294

TABLE 389            REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)            295

TABLE 390            REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS,  BY TYPE, 2023–2030 (USD MILLION) 295

TABLE 391            REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET,

BY TECHNOLOGY, 2023–2030 (USD MILLION)     296

TABLE 392            REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 296

TABLE 393            REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET,

BY END USER, 2023–2030 (USD MILLION)               297

TABLE 394            LATIN AMERICA: MACROECONOMIC INDICATORS      298

TABLE 395            LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY,  2023–2030 (USD MILLION)            298

TABLE 396            LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 299

TABLE 397            LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION)            299

TABLE 398            LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE,  2023–2030 (USD MILLION)            299

TABLE 399            LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE,  2023–2030 (USD MILLION)            300

TABLE 400            LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS,

BY TYPE, 2023–2030 (USD MILLION)         300

TABLE 401            LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY,  2023–2030 (USD MILLION)            301

TABLE 402            LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 301

TABLE 403            LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER,  2023–2030 (USD MILLION)            302

TABLE 404            BRAZIL: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,  2023–2030 (USD MILLION)                 303

TABLE 405            BRAZIL: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING,  2023–2030 (USD MILLION)                 303

TABLE 406            BRAZIL: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE,

2023–2030 (USD MILLION)            303

TABLE 407            BRAZIL: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE,

2023–2030 (USD MILLION)            304

TABLE 408            BRAZIL: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE,  2023–2030 (USD MILLION)                 304

TABLE 409            BRAZIL: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            305

TABLE 410            BRAZIL: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION,  2023–2030 (USD MILLION)            305

TABLE 411            BRAZIL: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER,

2023–2030 (USD MILLION)            306

TABLE 412            MEXICO: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,  2023–2030 (USD MILLION)                 307

TABLE 413            MEXICO: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING,  2023–2030 (USD MILLION)                 307

TABLE 414            MEXICO: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE,

2023–2030 (USD MILLION)            307

TABLE 415            MEXICO: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE,

2023–2030 (USD MILLION)            308

TABLE 416            MEXICO: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE,  2023–2030 (USD MILLION)                 308

TABLE 417            MEXICO: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            309

TABLE 418            MEXICO: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)                 309

TABLE 419            MEXICO: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER,

2023–2030 (USD MILLION)            310

TABLE 420            REST OF LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,

BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)        311

TABLE 421            REST OF LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION)            311

TABLE 422            REST OF LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,

BY SAMPLE TYPE, 2023–2030 (USD MILLION)       312

TABLE 423            REST OF LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,

BY DISEASE TYPE, 2023–2030 (USD MILLION)       312

TABLE 424            REST OF LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 313

TABLE 425            REST OF LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,

BY TECHNOLOGY, 2023–2030 (USD MILLION)     313

TABLE 426            REST OF LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,

BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)  313

TABLE 427            REST OF LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)            314

TABLE 428            MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS      315

TABLE 429            MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               316

TABLE 430            MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,

BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)        316

TABLE 431            MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION)            316

TABLE 432            MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)            317

TABLE 433            MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)            317

TABLE 434            MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS,  BY TYPE, 2023–2030 (USD MILLION) 318

TABLE 435            MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,

BY TECHNOLOGY, 2023–2030 (USD MILLION)     318

TABLE 436            MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,

BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)  319

TABLE 437            MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)            319

TABLE 438            KINGDOM OF SAUDI ARABIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,

BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)        320

TABLE 439            KINGDOM OF SAUDI ARABIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,

BY TYPE OF TESTING, 2023–2030 (USD MILLION)               320

TABLE 440            KINGDOM OF SAUDI ARABIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,

BY SAMPLE TYPE, 2023–2030 (USD MILLION)       320

TABLE 441            KINGDOM OF SAUDI ARABIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,

BY DISEASE TYPE, 2023–2030 (USD MILLION)       321

TABLE 442            KINGDOM OF SAUDI ARABIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)            321

TABLE 443            KINGDOM OF SAUDI ARABIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,

BY TECHNOLOGY, 2023–2030 (USD MILLION)     322

TABLE 444            KINGDOM OF SAUDI ARABIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,

BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)  322

TABLE 445            KINGDOM OF SAUDI ARABIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)            323

TABLE 446            UNITED ARAB EMIRATES: INFECTIOUS DISEASE DIAGNOSTICS MARKET,

BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)        324

TABLE 447            UNITED ARAB EMIRATES: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION)            324

TABLE 448            UNITED ARAB EMIRATES: INFECTIOUS DISEASE DIAGNOSTICS MARKET,

BY SAMPLE TYPE, 2023–2030 (USD MILLION)       324

TABLE 449            UNITED ARAB EMIRATES: INFECTIOUS DISEASE DIAGNOSTICS MARKET,

BY DISEASE TYPE, 2023–2030 (USD MILLION)       325

TABLE 450            UNITED ARAB EMIRATES: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 325

TABLE 451            UNITED ARAB EMIRATES: INFECTIOUS DISEASE DIAGNOSTICS MARKET,

BY TECHNOLOGY, 2023–2030 (USD MILLION)     326

TABLE 452            UNITED ARAB EMIRATES: INFECTIOUS DISEASE DIAGNOSTICS MARKET,

BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)  326

TABLE 453            UNITED ARAB EMIRATES: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)            327

TABLE 454            REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,  BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)            327

TABLE 455            REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,

BY TYPE OF TESTING, 2023–2030 (USD MILLION)               328

TABLE 456            REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,  BY SAMPLE TYPE, 2023–2030 (USD MILLION) 328

TABLE 457            REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,  BY DISEASE TYPE, 2023–2030 (USD MILLION) 329

TABLE 458            REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)            329

TABLE 459            REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,  BY TECHNOLOGY, 2023–2030 (USD MILLION) 330

TABLE 460            REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,  BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)            330

TABLE 461            REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,  BY END USER, 2023–2030 (USD MILLION) 331

TABLE 462            OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN THE INFECTIOUS DISEASE DIAGNOSTICS MARKET, JANUARY 2021−JUNE 2025        332

TABLE 463            INFECTIOUS DISEASE DIAGNOSTICS MARKET: DEGREE OF COMPETITION         335

TABLE 464            INFECTIOUS DISEASE DIAGNOSTICS MARKET: REGION FOOTPRINT     339

TABLE 465            INFECTIOUS DISEASE DIAGNOSTICS MARKET: PRODUCT & SERVICE FOOTPRINT           340

TABLE 466            INFECTIOUS DISEASE DIAGNOSTICS MARKET: TYPE OF TESTING FOOTPRINT 340

TABLE 467            INFECTIOUS DISEASE DIAGNOSTICS MARKET: SAMPLE TYPE FOOTPRINT          341

TABLE 468            INFECTIOUS DISEASE DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES             343

TABLE 469            INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2)                 343

TABLE 470            INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2)                 344

TABLE 471            INFECTIOUS DISEASE DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–JUNE 2025                 346

TABLE 472            INFECTIOUS DISEASE DIAGNOSTICS MARKET: DEALS, JANUARY 2021–JUNE 2025              347

TABLE 473            INFECTIOUS DISEASE DIAGNOSTICS MARKET: EXPANSIONS,

JANUARY 2021– JUNE 2025             348

TABLE 474            F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW          349

TABLE 475            F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED               350

TABLE 476            F. HOFFMANN-LA ROCHE LTD.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–JUNE 2025             353

TABLE 477            F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021−JUNE 2025            355

TABLE 478            F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2021–JUNE 2025              355

TABLE 479            ABBOTT: COMPANY OVERVIEW                357

TABLE 480            ABBOTT: PRODUCTS/SERVICES OFFERED                 358

TABLE 481            ABBOTT: PRODUCT/SERVICE LAUNCHES & APPROVALS,

JANUARY 2021–JUNE 2025              360

TABLE 482            ABBOTT: DEALS, JANUARY 2021−JUNE 2025                 361

TABLE 483            DANAHER CORPORATION: COMPANY OVERVIEW          362

TABLE 484            DANAHER CORPORATION: PRODUCTS/SERVICES OFFERED               363

TABLE 485            DANAHER CORPORATION: PRODUCT/SERVICE LAUNCHES & APPROVALS,

JANUARY 2021–JUNE 2025              365

TABLE 486            DANAHER CORPORATION: DEALS, JANUARY 2021–JUNE 2025  366

TABLE 487            DANAHER CORPORATION: EXPANSIONS, JANUARY 2021−JUNE 2025            367

TABLE 488            BIOMÉRIEUX: COMPANY OVERVIEW      368

TABLE 489            BIOMÉRIEUX: PRODUCTS/SERVICES OFFERED                 369

TABLE 490            BIOMÉRIEUX: PRODUCT/SERVICE LAUNCHES & APPROVALS,

JANUARY 2021–JUNE 2025              373

TABLE 491            BIOMÉRIEUX: DEALS, JANUARY 2021– JUNE 2025                 375

TABLE 492            THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW          377

TABLE 493            THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED               378

TABLE 494            THERMO FISHER SCIENTIFIC INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–JUNE 2025             380

TABLE 495            THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–JUNE 2025              381

TABLE 496            SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW          383

TABLE 497            SIEMENS HEALTHINEERS AG: PRODUCTS/SERVICES OFFERED               384

TABLE 498            SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES, JANUARY 2021–JUNE 2025     386

TABLE 499            SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2021−JUNE 2025                386

TABLE 500            SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2021−JUNE 2025            387

TABLE 501            HOLOGIC, INC.: COMPANY OVERVIEW  388

TABLE 502            HOLOGIC, INC.: PRODUCTS/SERVICES OFFERED             389

TABLE 503            HOLOGIC, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS,

JANUARY 2021–JUNE 2025              390

TABLE 504            HOLOGIC, INC.: DEALS, JANUARY 2021– JUNE 2025        391

TABLE 505            BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW   392

TABLE 506            BECTON, DICKINSON AND COMPANY: PRODUCTS/SERVICES OFFERED               393

TABLE 507            BECTON, DICKINSON AND COMPANY: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–JUNE 2025             396

TABLE 508            BD: DEALS, JANUARY 2021–JUNE 2025      397

TABLE 509            BD: EXPANSIONS, JANUARY 2021– JUNE 2025                 398

TABLE 510            REVVITY, INC.: COMPANY OVERVIEW    399

TABLE 511            REVVITY, INC.: PRODUCTS/SERVICES OFFERED                 400

TABLE 512            REVVITY INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS,

JANUARY 2021–JUNE 2025              402

TABLE 513            QIAGEN N.V.: COMPANY OVERVIEW       403

TABLE 514            QIAGEN N.V.: PRODUCTS/SERVICES OFFERED                 404

TABLE 515            QIAGEN N.V.: PRODUCT/SERVICE LAUNCHES & APPROVALS,

JANUARY 2021–JUNE 2025              406

TABLE 516            QIAGEN N.V.: DEALS, JANUARY 2021–JUNE 2025                 408

TABLE 517            QIAGEN N.V.: EXPANSIONS, JANUARY 2021–JUNE 2025        408

TABLE 518            SEEGENE INC.: COMPANY OVERVIEW    409

TABLE 519            SEEGENE INC.: PRODUCTS/SERVICES OFFERED                 410

TABLE 520            SEEGENE INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS,

JANUARY 2021–JUNE 2025              411

TABLE 521            SEEGENE INC.: DEALS, JANUARY 2021– JUNE 2025                 412

TABLE 522            SEEGENE INC.: EXPANSIONS, JANUARY 2021– JUNE 2025             413

TABLE 523            QUIDELORTHO CORPORATION: COMPANY OVERVIEW          414

TABLE 524            GRIFOLS, S.A.: COMPANY OVERVIEW      416

TABLE 525            DIASORIN S.P.A.: COMPANY OVERVIEW 417

TABLE 526            BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW          419

TABLE 527            SYSMEX CORPORATION: COMPANY OVERVIEW                 421

TABLE 528            ORASURE TECHNOLOGIES, INC.: COMPANY OVERVIEW          422

TABLE 529            CO-DIAGNOSTICS, INC.: COMPANY OVERVIEW                 423

TABLE 530            SD BIOSENSOR, INC.: COMPANY OVERVIEW                 424

TABLE 531            BIOSYNEX SA: COMPANY OVERVIEW      425

TABLE 532            TRINITY BIOTECH: COMPANY OVERVIEW                 427

TABLE 533            BRUKER (ELITECHGROUP): COMPANY OVERVIEW          428

TABLE 534            GENETIC SIGNATURES: COMPANY OVERVIEW                 430

TABLE 535            EPITOPE DIAGNOSTICS, INC.: COMPANY OVERVIEW          430

TABLE 536            TRIVITRON HEALTHCARE: COMPANY OVERVIEW          431

TABLE 537            MERIL LIFE SCIENCES PVT. LTD.: COMPANY OVERVIEW          432

TABLE 538            INBIOS INTERNATIONAL, INC.: COMPANY OVERVIEW          433

TABLE 539            UNIOGEN OY: COMPANY OVERVIEW      434

TABLE 540            VELA DIAGNOSTICS: COMPANY OVERVIEW                 435

TABLE 541            MOLBIO DIAGNOSTICS LIMITED: COMPANY OVERVIEW          436

LIST OF FIGURES

FIGURE 1              INFECTIOUS DISEASE DIAGNOSTICS MARKET SEGMENTATION & REGIONAL SCOPE    40

FIGURE 2              INFECTIOUS DISEASE DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY      44

FIGURE 3              PRIMARY SOURCES         47

FIGURE 4              BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS            50

FIGURE 5              BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,

AND REGION     50

FIGURE 6              BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH              51

FIGURE 7              CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS T                 52

FIGURE 8              INFECTIOUS DISEASE DIAGNOSTICS MARKET: TOP-DOWN APPROACH                54

FIGURE 9              DATA TRIANGULATION METHODOLOGY                 55

FIGURE 10            INFECTIOUS DISEASE DIAGNOSTICS MARKET: RESEARCH ASSUMPTIONS           56

FIGURE 11            INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,

2025 VS. 2030 (USD MILLION)      58

FIGURE 12            INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING,

2025 VS. 2030 (USD MILLION)      59

FIGURE 13            INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE,

2025 VS. 2030 (USD MILLION)      59

FIGURE 14            INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY,

2025 VS. 2030 (USD MILLION)      60

FIGURE 15            INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE,

2025 VS. 2030 (USD MILLION)      61

FIGURE 16            INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION,

2025 VS. 2030 (USD MILLION)      62

FIGURE 17            INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER,

2025 VS. 2030 (USD MILLION)      62

FIGURE 18            INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION,

2025 VS. 2030 (USD MILLION)      63

FIGURE 19            RISING FOCUS ON R&D FOR INFECTIOUS DISEASE DIAGNOSTICS TO PROPEL MARKET     64

FIGURE 20            REAGENTS, KITS, AND CONSUMABLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD                 65

FIGURE 21            LABORATORY TESTING SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD            65

FIGURE 22            BLOOD, SERUM, AND PLASMA SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD            66

FIGURE 23            HEPATITIS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD       66

FIGURE 24            IMMUNODIAGNOSTICS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD            67

FIGURE 25            DIAGNOSTICS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD    67

FIGURE 26            DIAGNOSTIC LABORATORIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD            68

FIGURE 27            ASIA PACIFIC REGION TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD      68

FIGURE 28            INFECTIOUS DISEASE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES                 69

FIGURE 29            PATENT ANALYSIS FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES (JANUARY 2015–DECEMBER 2024)              79

FIGURE 30            VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING & ASSEMBLY PHASES             81

FIGURE 31            INFECTIOUS DISEASE DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS             83

FIGURE 32            INFECTIOUS DISEASE DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS  85

FIGURE 33            INFECTIOUS DISEASE DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS           86

FIGURE 34            INFECTIOUS DISEASE DIAGNOSTICS MARKET: TRENDS & DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES                 98

FIGURE 35            INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS                 99

FIGURE 36            KEY BUYING CRITERIA FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS           99

FIGURE 37            NUMBER OF DEALS & FUNDING ACTIVITIES IN INFECTIOUS DISEASE DIAGNOSTICS MARKET   100

FIGURE 38            MARKET POTENTIAL OF AI IN INFECTIOUS DISEASE DIAGNOSTICS MARKET               103

FIGURE 39            NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT         230

FIGURE 40            ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT         274

FIGURE 41            REVENUE ANALYSIS OF KEY PLAYERS IN INFECTIOUS DISEASE DIAGNOSTICS MARKET (2022–2024)                 334

FIGURE 42            MARKET SHARE ANALYSIS OF KEY PLAYERS IN INFECTIOUS DISEASE DIAGNOSTICS MARKET (2024)      335

FIGURE 43            INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX

(KEY PLAYERS), 2024       338

FIGURE 44            INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPANY FOOTPRINT 339

FIGURE 45            INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024                 342

FIGURE 46            EV/EBITDA OF KEY VENDORS   344

FIGURE 47            YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS      345

FIGURE 48            INFECTIOUS DISEASE DIAGNOSTICS MARKET: BRAND COMPARISON FOR INSTRUMENTS           346

FIGURE 49            F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024)             350

FIGURE 50            ABBOTT: COMPANY SNAPSHOT (2024)  358

FIGURE 51            DANAHER CORPORATION: COMPANY SNAPSHOT (2024)             363

FIGURE 52            BIOMÉRIEUX: COMPANY SNAPSHOT (2024)                 369

FIGURE 53            THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)             378

FIGURE 54            SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2024)             384

FIGURE 55            HOLOGIC, INC.: COMPANY SNAPSHOT (2024)                 389

FIGURE 56            BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2024)      393

FIGURE 57            REVVITY, INC.: COMPANY SNAPSHOT (2024)                 400

FIGURE 58            QIAGEN N.V.: COMPANY SNAPSHOT (2024)                 404

FIGURE 59            SEEGENE INC.: COMPANY SNAPSHOT (2024)                 410

MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ライセンスタイプ4

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
• 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
• ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11

MarketsandMarkets  出版レポート一覧